Granules India

Price chart

Previous close

₹800.55

Open

₹800.55

Day high

₹808.00

Day low

₹786.10

Listed on NSE since 20 June 2005.

Market value

₹21,813 Cr

P/E (trailing)

27.99

EPS (trailing)

₹28.57

Price to book

3.07

Dividend yield

0.22%

Return on equity

13.5%

Debt to equity

0.17

Profit margin

12.1%

Volume today

10.43 L

Average volume

9.99 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Granules India’s results filed with NSE, consolidated (the whole group). Net profit is the share of Granules India’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Granules India’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Hyderabad

Employees

4,306

Company website · Profile: Yahoo Finance

No headlines name Granules India in the last day or two.

• Dividend - Rs 1.75 Per Share

  Dividend · ex-date 30 July 2026

• Dividend - Rs 1.50 Per Share

  Dividend · ex-date 31 July 2025

• Annual General Meeting/Dividend - Rs 1.50 Per Share

  Dividend · ex-date 30 July 2024

• Dividend - Rs 1.50 Per Share

  Dividend · ex-date 3 August 2023

• Annual General Meeting

  Action · ex-date 3 August 2023

• Buy Back

  Buyback · ex-date 22 August 2022 · record date 23 August 2022

• Annual General Meeting/Dividend - Rs 0.75 Per Share

  Dividend · ex-date 19 July 2022

• Interim Dividend - Rs 0.25 Per Share

  Dividend · ex-date 17 February 2022 · record date 18 February 2022

Source: NSE. Latest first, 8 of 20.